HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTC BB:ARDM.OB) (“Aradigm” or the “Company”) announced that it has received the $5 million milestone payment from Grifols S.A. for the dosing of the first patient in the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm’s proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).
Help employers find you! Check out all the jobs and post your resume.